Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a new antihyperglycemic class with the demonstrated advantage of reducing major adverse cardiovascular events (MACE) among individuals with type 2 diabetes (T2DM), atherosclerotic cardiovascular disease, or high cardiovascular risk.
Objective: Τo summarize the evidence of systematic reviews (SRs) that assess MACE (cardiovascular mortality, nonfatal myocardial infarction, and stroke) and hospitalizations for heart failure in GLP-1RAs-treated patients and to evaluate possible overlap in pertinent SRs.
Methods: We performed a comprehensive search via MEDLINE, Cochrane Library, and PROSPERO databases up to February 23, 2020, for SRs examining cardiovascular outcomes of GLP-1RAs in T2DM patients. Three independent authors extracted data and assessed the methodological quality of the included SRs using the ROBIS tool.
Results: We found 37 SRs – published between 2009 and 2020 in English – of which 35 collected data only from randomized clinical trials while two from observational studies as well. The methodological quality of the 37 SRs ranged from low to high, while only 3 have evaluated the overall quality of evidence outcome using the Grading of Recommendations Assessments, Development and Evaluation (GRADE) approach. All the included SRs showed cardiovascular safety of GLP-1RAs while the latest ones demonstrated a reduction in composite MACE endpoint as well as its every individual component and heart failure hospitalizations.
Conclusion: In the first overview of SRs about cardiovascular outcomes of GLP-1RAs, they proved favorable effects on reducing cardiovascular events in T2DM patients. There are, however, many overlapping reviews based on relatively few cardiovascular outcomes trials.
[http://dx.doi.org/10.2174/1573399812666151016101622] [PMID: 26472574]
[http://dx.doi.org/10.1093/eurheartj/ehv728] [PMID: 26819227]
[http://dx.doi.org/10.1093/eurheartj/ehy596] [PMID: 30295797]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.032038] [PMID: 29133604]
[http://dx.doi.org/10.1093/eurheartj/ehx511] [PMID: 29020355]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.034222] [PMID: 29526832]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042929] [PMID: 31524498]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037778] [PMID: 30586757]
[http://dx.doi.org/10.1002/ejhf.1713] [PMID: 31912605]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038881] [PMID: 31009585]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044235] [PMID: 31707794]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.042375] [PMID: 31434508]
[http://dx.doi.org/10.1002/ejhf.1473] [PMID: 31033127]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036459] [PMID: 30884964]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.120.045691] [PMID: 32410463]
[http://dx.doi.org/10.1111/dom.13297] [PMID: 29569427]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024764] [PMID: 27956401]
[http://dx.doi.org/10.1056/NEJMoa1515920] [PMID: 27299675]
[http://dx.doi.org/10.2337/dci18-0033] [PMID: 30291106]
[http://dx.doi.org/10.1111/dom.14015] [PMID: 32227432]